Scroll

perphenazine 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
	2113	58-39-9

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: perphenazine perfenazine perfenil perphenan perphenazin thilatazin tranquisan perphanzine	An antipsychotic phenothiazine derivative with actions and uses similar to those of CHLORPROMAZINE. Molecular weight: 403.97 Formula: C21H26ClN3OS CLOGP: 4.01 LIPINSKI: 0 HAC: 4 HDO: 1 TPSA: 29.95 ALOGS: -4.23 ROTB: 6 Status: OFP Legend: OFP - off patent OFM - off market ONP - on patent

Molecule

Description

Molfile Inchi Smiles

Synonyms:

perphenazine
perfenazine
perfenil
perphenan
perphenazin
thilatazin
tranquisan
perphanzine

An antipsychotic phenothiazine derivative with actions and uses similar to those of CHLORPROMAZINE.

Molecular weight: 403.97
Formula: C21H26ClN3OS
CLOGP: 4.01
LIPINSKI: 0
HAC: 4
HDO: 1
TPSA: 29.95
ALOGS: -4.23
ROTB: 6

Status: OFP

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

Dose	Unit	Route
30	mg	O
7	mg	P
10	mg	P
16	mg	R

ADMET properties:

Property	Value	Reference
MRTD (Maximum Recommended Therapeutic Daily Dose)	0.99 µM/kg/day	Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability)	40 %	Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution)	18 L/kg	Lombardo F, Berellini G, Obach RS
CL (Clearance)	27 mL/min/kg	Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma)	0.07 %	Lombardo F, Berellini G, Obach RS
t_half (Half-life)	9.40 hours	Lombardo F, Berellini G, Obach RS
S (Water solubility)	0.02 mg/mL	Bocci G, Oprea TI, Benet LZ
BDDCS (Biopharmaceutical Drug Disposition Classification System)	2	Bocci G, Oprea TI, Benet LZ

Approvals:

Date	Agency	Company	Orphan
Feb. 27, 1957	FDA

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Blood magnesium increased	79.69	27.36	20	2870	3018	63483114
Pleural fibrosis	77.04	27.36	20	2870	3452	63482680
Presbyacusis	75.84	27.36	19	2871	2846	63483286
Pleural thickening	75.72	27.36	19	2871	2864	63483268
Tardive dyskinesia	71.43	27.36	23	2867	8479	63477653
Deafness neurosensory	65.91	27.36	19	2871	4836	63481296
Sopor	62.88	27.36	27	2863	22137	63463995
Drug abuse	60.83	27.36	39	2851	72479	63413653
Neuroleptic malignant syndrome	59.83	27.36	22	2868	12034	63474098
Epigastric discomfort	59.65	27.36	19	2871	6761	63479371
Mitochondrial encephalomyopathy	53.04	27.36	7	2883	22	63486110
Cyst	49.49	27.36	20	2870	14079	63472053
Ileus paralytic	45.23	27.36	14	2876	4537	63481595
Blood potassium increased	44.46	27.36	20	2870	18289	63467843
Osteopenia	42.97	27.36	20	2870	19765	63466367
Extrapyramidal disorder	40.37	27.36	17	2873	13267	63472865
Bone cyst	35.91	27.36	10	2880	2244	63483888
Deformity	35.66	27.36	15	2875	11669	63474463
Moaning	34.74	27.36	8	2882	838	63485294
Skin lesion	34.67	27.36	20	2870	30701	63455431
Osteosclerosis	34.62	27.36	11	2879	3877	63482255
Hyperprolactinaemia	34.59	27.36	11	2879	3889	63482243
Intentional self-injury	32.43	27.36	18	2872	25669	63460463
Onychophagia	31.32	27.36	5	2885	72	63486060
Multiple drug therapy	31.17	27.36	10	2880	3636	63482496
Metabolic syndrome	29.74	27.36	8	2882	1580	63484552
Dry eye	29.47	27.36	20	2870	40741	63445391
Muscle rigidity	29.31	27.36	13	2877	11487	63474645
Toxicity to various agents	28.82	27.36	45	2845	247205	63238927
Bradykinesia	27.71	27.36	10	2880	5178	63480954
Overdose	27.70	27.36	30	2860	115048	63371084
Sports injury	27.43	27.36	4	2886	30	63486102

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Akathisia	464.17	46.23	111	2648	7998	34946174
Antipsychotic drug level below therapeutic	461.05	46.23	90	2669	2457	34951715
Therapeutic product effect variable	445.85	46.23	87	2672	2369	34951803
Disinhibition	439.83	46.23	90	2669	3136	34951036
Obsessive-compulsive disorder	434.16	46.23	98	2661	5466	34948706
Euphoric mood	400.43	46.23	92	2667	5549	34948623
Increased appetite	365.08	46.23	90	2669	7339	34946833
Suicide attempt	238.63	46.23	96	2663	39020	34915152
Therapeutic product effect incomplete	189.54	46.23	88	2671	50453	34903719
Leukaemia	177.44	46.23	46	2713	4557	34949615
Leukopenia	168.39	46.23	87	2672	62769	34891403
Dyslipidaemia	164.06	46.23	48	2711	7440	34946732
Weight increased	162.18	46.23	97	2662	92936	34861236
Toxicity to various agents	159.94	46.23	129	2630	200233	34753939
Obesity	134.59	46.23	47	2712	12831	34941341
Prescribed overdose	123.44	46.23	42	2717	10605	34943567
Drug ineffective	73.12	46.23	129	2630	456622	34497550
Schizoaffective disorder	69.68	46.23	17	2742	1310	34952862
Neuroleptic malignant syndrome	69.37	46.23	32	2727	17902	34936270
Irritability	54.11	46.23	30	2729	24660	34929512

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Akathisia	163.14	27.36	50	4271	13209	79726858
Antipsychotic drug level below therapeutic	123.16	27.36	25	4296	1213	79738854
Therapeutic product effect variable	116.56	27.36	26	4295	1983	79738084
Neuroleptic malignant syndrome	106.56	27.36	44	4277	27515	79712552
Disinhibition	104.70	27.36	25	4296	2573	79737494
Obsessive-compulsive disorder	93.06	27.36	27	4294	5900	79734167
Euphoric mood	86.00	27.36	27	4294	7699	79732368
Toxicity to various agents	75.73	27.36	103	4218	421437	79318630
Dyslipidaemia	75.16	27.36	27	4294	11606	79728461
Presbyacusis	73.93	27.36	19	4302	2641	79737426
Blood magnesium increased	73.37	27.36	20	4301	3486	79736581
Pleural thickening	71.78	27.36	19	4302	2963	79737104
Increased appetite	67.00	27.36	25	4296	11953	79728114
Tardive dyskinesia	66.28	27.36	24	4297	10547	79729520
Pleural fibrosis	65.49	27.36	19	4302	4148	79735919
Completed suicide	59.85	27.36	70	4251	245697	79494370
Deafness neurosensory	56.06	27.36	19	4302	6879	79733188
Hyperprolactinaemia	54.79	27.36	17	4304	4659	79735408
Epigastric discomfort	53.54	27.36	19	4302	7877	79732190
Ileus paralytic	53.51	27.36	20	4301	9600	79730467
Enuresis	52.21	27.36	15	4306	3161	79736906
Obesity	51.98	27.36	29	4292	35096	79704971
Sopor	50.89	27.36	28	4293	32982	79707085
Mitochondrial encephalomyopathy	50.11	27.36	7	4314	30	79740037
Schizoaffective disorder	48.42	27.36	13	4308	2139	79737928
Cyst	46.46	27.36	20	4301	13820	79726247
Intentional self-injury	45.89	27.36	26	4295	32393	79707674
Suicide attempt	45.62	27.36	37	4284	82895	79657172
Irritability	42.64	27.36	27	4294	41117	79698950
Osteopenia	38.07	27.36	19	4302	18345	79721722
Drug abuse	37.32	27.36	45	4276	162646	79577421
Muscle rigidity	36.64	27.36	19	4302	19863	79720204
Prescribed overdose	34.68	27.36	23	4298	37860	79702207
Extrapyramidal disorder	34.29	27.36	19	4302	22660	79717407
Deformity	32.63	27.36	14	4307	9591	79730476
Sedation	32.49	27.36	25	4296	51870	79688197
Blood potassium increased	32.31	27.36	20	4301	29255	79710812
Bradyphrenia	31.25	27.36	14	4307	10626	79729441
Moaning	31	27.36	8	4313	1129	79738938
Weight increased	30.27	27.36	54	4267	277332	79462735
Bone cyst	30.04	27.36	10	4311	3423	79736644
Onychophagia	28.67	27.36	5	4316	105	79739962
Osteosclerosis	28.62	27.36	10	4311	3961	79736106
Multiple drug therapy	28.36	27.36	10	4311	4068	79735999
Dry eye	28.08	27.36	20	4301	36911	79703156

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	N05AB03	NERVOUS SYSTEM PSYCHOLEPTICS ANTIPSYCHOTICS Phenothiazines with piperazine structure
FDA CS	M0016525	Phenothiazines
MeSH PA	D014150	Antipsychotic Agents
MeSH PA	D002491	Central Nervous System Agents
MeSH PA	D002492	Central Nervous System Depressants
MeSH PA	D015259	Dopamine Agents
MeSH PA	D018492	Dopamine Antagonists
MeSH PA	D018377	Neurotransmitter Agents
MeSH PA	D011619	Psychotropic Drugs
MeSH PA	D014149	Tranquilizing Agents
CHEBI has role	CHEBI:37930	phenothiazine antipsychotic drugs
CHEBI has role	CHEBI:48561	dopaminergic antagonists
CHEBI has role	CHEBI:50919	antiemetico
FDA EPC	N0000175746	Phenothiazine

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Nausea and vomiting	indication	16932000
Schizophrenia	indication	58214004	DOID:5419
Mixed anxiety and depressive disorder	indication	231504006
Suicidal thoughts	contraindication	6471006
Alcoholism	contraindication	7200002
Organophosphate poisoning	contraindication	8260003
Weight gain finding	contraindication	8943002
Sinus tachycardia	contraindication	11092001
Neuroleptic malignant syndrome	contraindication	15244003	DOID:14464
Senile dementia	contraindication	15662003
Chronic disease of respiratory system	contraindication	17097001
Myocardial infarction	contraindication	22298006	DOID:5844
Glaucoma	contraindication	23986001	DOID:1686
Orthostatic hypotension	contraindication	28651003
Torsades de pointes	contraindication	31722008
Parkinsonism	contraindication	32798002
Hyperthyroidism	contraindication	34486009	DOID:7998
Conduction disorder of the heart	contraindication	44808001
Chronic heart failure	contraindication	48447003
Bradycardia	contraindication	48867003
Paralytic ileus	contraindication	55525008	DOID:8442
Extrapyramidal disease	contraindication	76349003
Hyperglycemia	contraindication	80394007	DOID:4195
Chronic idiopathic constipation	contraindication	82934008
Open-angle glaucoma	contraindication	84494001	DOID:1067
Epilepsy	contraindication	84757009	DOID:1826
Leukopenia	contraindication	84828003	DOID:615
Stupor	contraindication	89458003
Tardive dyskinesia	contraindication	102449007
Prolonged QT interval	contraindication	111975006
Acute disease of cardiovascular system	contraindication	128487001
Bipolar affective disorder, current episode manic	contraindication	191618007
Angina pectoris	contraindication	194828000
Disease of liver	contraindication	235856003	DOID:409
Metabolic syndrome X	contraindication	237602007	DOID:14221
Hyperprolactinemia	contraindication	237662005	DOID:12700
Benign prostatic hyperplasia	contraindication	266569009
Retention of urine	contraindication	267064002
Syncope	contraindication	271594007
Anemia	contraindication	271737000	DOID:2355
Thrombocytopenic disorder	contraindication	302215000	DOID:1588
Neutropenic disorder	contraindication	303011007	DOID:1227
Coma	contraindication	371632003
At risk for aspiration	contraindication	371736008
Angle-closure glaucoma	contraindication	392291006	DOID:13550
Visual impairment	contraindication	397540003
Breastfeeding (mother)	contraindication	413712001
Myocardial ischemia	contraindication	414795007	DOID:3393
Obesity	contraindication	414916001	DOID:9970
Myocardial infarction in recovery phase	contraindication	418044006
Congenital long QT syndrome	contraindication	442917000
Carcinoma of female breast	contraindication	447782002

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	8.21	Basic
pKa2	4.21	Basic
pKa3	2.21	Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Bioact source	MoA source
D(2) dopamine receptor	GPCR	P14416	DRD2_HUMAN	ANTAGONIST	Ki	9.32	WOMBAT-PK	CHEMBL
5-hydroxytryptamine receptor 1A	GPCR	P08908	5HT1A_HUMAN		Ki	6.07	WOMBAT-PK
5-hydroxytryptamine receptor 2A	GPCR	P28223	5HT2A_HUMAN		Ki	8.25	WOMBAT-PK
Alpha-2A adrenergic receptor	GPCR	P08913	ADA2A_HUMAN		Ki	6.19	WOMBAT-PK
Potassium voltage-gated channel subfamily H member 2	Ion channel	Q12809	KCNH2_HUMAN		Ki	5.46	DRUG MATRIX
5-hydroxytryptamine receptor 6	GPCR	P50406	5HT6R_HUMAN		Ki	7.55	WOMBAT-PK
5-hydroxytryptamine receptor 7	GPCR	P34969	5HT7R_HUMAN		Ki	7.64	WOMBAT-PK
Alpha-1A adrenergic receptor	GPCR	P35348	ADA1A_HUMAN		Ki	8	WOMBAT-PK
Alpha-2B adrenergic receptor	GPCR	P18089	ADA2B_HUMAN		Ki	6.98	WOMBAT-PK
D(3) dopamine receptor	GPCR	P35462	DRD3_HUMAN		Ki	9.52	WOMBAT-PK
Histamine H1 receptor	GPCR	P35367	HRH1_HUMAN		Ki	8.09	WOMBAT-PK
Muscarinic acetylcholine receptor M3	GPCR	P20309	ACM3_HUMAN		Ki	5.73	PDSP
Aldehyde oxidase	Enzyme	Q06278	AOXA_HUMAN		IC50	7.48	WOMBAT-PK
Alpha-2C adrenergic receptor	GPCR	P18825	ADA2C_HUMAN		Ki	7.07	WOMBAT-PK
D(4) dopamine receptor	GPCR	P21917	DRD4_HUMAN		Ki	7.59	WOMBAT-PK
Retinal dehydrogenase 1	Enzyme	P00352	AL1A1_HUMAN		IC50	6.28	CHEMBL
5-hydroxytryptamine receptor 2C	GPCR	P28335	5HT2C_HUMAN		Ki	6.88	WOMBAT-PK
5-hydroxytryptamine receptor 7	GPCR		5HT7R_RAT	ANTAGONIST	Ki	7.60	IUPHAR
5-hydroxytryptamine receptor 6	GPCR		5HT6R_RAT	ANTAGONIST	Ki	7.80	IUPHAR
Pleiotropic ABC efflux transporter of multiple drugs	Transporter		PDR5_YEAST		IC50	5.85	CHEMBL

External reference:

ID	Source
4017939	VUID
N0000146289	NUI
D00503	KEGG_DRUG
4017939	VANDF
C0031184	UMLSCUI
CHEBI:8028	CHEBI
CHEMBL567	ChEMBL_ID
D010546	MESH_DESCRIPTOR_UI
DB00850	DRUGBANK_ID
4748	PUBCHEM_CID
209	IUPHAR_LIGAND_ID
637	INN_ID
FTA7XXY4EZ	UNII
8076	RXNORM
2271	MMSL
5261	MMSL
d00855	MMSL
001477	NDDF
387229007	SNOMEDCT_US
41147003	SNOMEDCT_US

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Perphenazine and Amitriptyline Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	2	0378-0042	TABLET, FILM COATED	4 mg	ORAL	ANDA	20 sections
Perphenazine and Amitriptyline Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	2	0378-0042	TABLET, FILM COATED	4 mg	ORAL	ANDA	20 sections
Perphenazine and Amitriptyline Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	2	0378-0073	TABLET, FILM COATED	4 mg	ORAL	ANDA	20 sections
Perphenazine and Amitriptyline Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	2	0378-0073	TABLET, FILM COATED	4 mg	ORAL	ANDA	20 sections
Perphenazine and Amitriptyline Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	2	0378-0330	TABLET, FILM COATED	2 mg	ORAL	ANDA	20 sections
Perphenazine and Amitriptyline Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	2	0378-0330	TABLET, FILM COATED	2 mg	ORAL	ANDA	20 sections
Perphenazine and Amitriptyline Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	2	0378-0442	TABLET, FILM COATED	2 mg	ORAL	ANDA	20 sections
Perphenazine and Amitriptyline Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	2	0378-0442	TABLET, FILM COATED	2 mg	ORAL	ANDA	20 sections
Perphenazine and Amitriptyline Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	2	0378-0574	TABLET, FILM COATED	4 mg	ORAL	ANDA	20 sections
Perphenazine and Amitriptyline Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	2	0378-0574	TABLET, FILM COATED	4 mg	ORAL	ANDA	20 sections
Perphenazine	HUMAN PRESCRIPTION DRUG LABEL	1	0378-5350	TABLET, FILM COATED	2 mg	ORAL	ANDA	18 sections
Perphenazine	HUMAN PRESCRIPTION DRUG LABEL	1	0378-5351	TABLET, FILM COATED	4 mg	ORAL	ANDA	18 sections
Perphenazine	HUMAN PRESCRIPTION DRUG LABEL	1	0378-5352	TABLET, FILM COATED	8 mg	ORAL	ANDA	18 sections
Perphenazine	HUMAN PRESCRIPTION DRUG LABEL	1	0378-5353	TABLET, FILM COATED	16 mg	ORAL	ANDA	18 sections
Perphenazine	HUMAN PRESCRIPTION DRUG LABEL	1	0591-4101	TABLET, FILM COATED	2 mg	ORAL	ANDA	20 sections
Perphenazine	HUMAN PRESCRIPTION DRUG LABEL	1	0591-4102	TABLET, FILM COATED	4 mg	ORAL	ANDA	20 sections
Perphenazine	HUMAN PRESCRIPTION DRUG LABEL	1	0591-4103	TABLET, FILM COATED	8 mg	ORAL	ANDA	20 sections
Perphenazine	HUMAN PRESCRIPTION DRUG LABEL	1	0591-4104	TABLET, FILM COATED	16 mg	ORAL	ANDA	20 sections
Perphenazine	HUMAN PRESCRIPTION DRUG LABEL	1	0603-5060	TABLET, FILM COATED	2 mg	ORAL	ANDA	19 sections
Perphenazine	HUMAN PRESCRIPTION DRUG LABEL	1	0603-5060	TABLET, FILM COATED	2 mg	ORAL	ANDA	19 sections
Perphenazine	HUMAN PRESCRIPTION DRUG LABEL	1	0603-5061	TABLET, FILM COATED	4 mg	ORAL	ANDA	19 sections
Perphenazine	HUMAN PRESCRIPTION DRUG LABEL	1	0603-5061	TABLET, FILM COATED	4 mg	ORAL	ANDA	19 sections
Perphenazine	HUMAN PRESCRIPTION DRUG LABEL	1	0603-5062	TABLET, FILM COATED	8 mg	ORAL	ANDA	19 sections
Perphenazine	HUMAN PRESCRIPTION DRUG LABEL	1	0603-5062	TABLET, FILM COATED	8 mg	ORAL	ANDA	19 sections
Perphenazine	HUMAN PRESCRIPTION DRUG LABEL	1	0603-5063	TABLET, FILM COATED	16 mg	ORAL	ANDA	19 sections
Perphenazine	HUMAN PRESCRIPTION DRUG LABEL	1	0603-5063	TABLET, FILM COATED	16 mg	ORAL	ANDA	19 sections
Perphenazine	HUMAN PRESCRIPTION DRUG LABEL	1	0781-8046	TABLET, FILM COATED	2 mg	ORAL	ANDA	20 sections
Perphenazine	HUMAN PRESCRIPTION DRUG LABEL	1	0781-8046	TABLET, FILM COATED	2 mg	ORAL	ANDA	20 sections
Perphenazine	HUMAN PRESCRIPTION DRUG LABEL	1	0781-8047	TABLET, FILM COATED	4 mg	ORAL	ANDA	20 sections
Perphenazine	HUMAN PRESCRIPTION DRUG LABEL	1	0781-8047	TABLET, FILM COATED	4 mg	ORAL	ANDA	20 sections